Background <p>Natural killer (NK) cells are key effectors in antitumor immunity, yet their function is markedly suppressed by transforming growth factor-β (TGF-β) in the tumor microenvironment. SMAD7 is an established intracellular antagonist of TGF-β signaling, but its specific role within NK cells remains poorly defined.</p> Methods <p>The clinical relevance of SMAD7 in tumor-infiltrating NK cells was evaluated via integrative analyses…
SMAD7 drives natural killer cell antitumor activity through canonical TGF-{beta} blockade and non-canonical transcriptional activation of STAT5A
Journal for ImmunoTherapy of Cancer | | Li, J., Liu, T., Xiao, W., Zhao, D., Li, Q., Liu, S., Li, X., Tong, Y., Li, H., Jiang, H., Wu, S., Li, Z., Tu, H., Gan, Y.
Topics: new-technology
Read the full article at Journal for ImmunoTherapy of Cancer